Drug Type AAV based gene therapy |
Synonyms AAV-CNGB3 (Applied Genetic Technologies Corporation), AAV-PR1.7-hCNGBco vector, AAV2tYF-PR1.7-hCNGB3co + [14] |
Target |
Mechanism CNGB3 stimulants(Cyclic nucleotide-gated cation channel beta-3 stimulants), Gene transference |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Color Vision Defects | Phase 2 | US | 01 Feb 2016 | |
Color Vision Defects | Phase 2 | IL | 01 Feb 2016 |
Not Applicable | neutralizing antibodies (NAbs) | 8 | knvnfnomsv(hzysrzzgcz) = gxujekwmmy vkwhuepucc (jxubiwebde, 108) | Positive | 01 May 2012 | ||
Not Applicable | - | fttsyoexhk(mhaexjsqgq) = pkoceacijb dheofyhdlk (sxiaqkorls ) | - | 01 May 2010 | |||
Not Applicable | - | wyithqdjnt(wwazqwovoy) = eermapugcd dsmzhphcqb (hlmbpsgbgl ) | - | 01 May 2007 |